Genmab A/S (GMAB)

NASDAQ: GMAB · IEX Real-Time Price · USD
36.49
-0.75 (-2.01%)
Aug 16, 2022 11:41 AM EDT - Market open
-2.01%
Market Cap 23.83B
Revenue (ttm) 1.43B
Net Income (ttm) 556.46M
Shares Out 653.03M
EPS (ttm) 0.51
PE Ratio 71.55
Forward PE 49.02
Dividend n/a
Ex-Dividend Date n/a
Volume 186,044
Open 36.57
Previous Close 37.24
Day's Range 35.96 - 36.66
52-Week Range 26.19 - 49.07
Beta 0.64
Analysts Buy
Price Target 37.84 (+3.7%)
Earnings Date Aug 10, 2022

About GMAB

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL a... [Read more...]

Industry Biotechnology
Founded 1999
CEO Jan van de Winkel
Employees 1,445
Stock Exchange NASDAQ
Ticker Symbol GMAB
Full Company Profile

Financial Performance

In 2021, Genmab's revenue was 8.48 billion, a decrease of -16.11% compared to the previous year's 10.11 billion. Earnings were 3.01 billion, a decrease of -36.78%.

Financial numbers in DKK Financial Statements

Analyst Forecast

According to 35 analysts, the average rating for GMAB stock is "Buy." The 12-month stock price forecast is 37.84, which is an increase of 3.70% from the latest price.

Price Target
$37.84
(3.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Transactions in connection with share buy-back program

Company Announcement

Genmab Announces Financial Results for the First Half of 2022

August 10 , 202 2 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2022

Genmab Improves Its 2022 Financial Guidance

Company Announcement

Transactions in connection with share buy-back program

Company Announcement

Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced an expansion of their global strategic collaboration to develop and commerciali...

Other symbols: BNTX

Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcorit...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that AbbVie (NYSE: ABBV) will submit a conditional marketing authorization application (MAA) with the European Medicines A...

Other symbols: ABBV

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement

Genmab Announces Initiation of Share Buy-Back Program

Company Announcement

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/R...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE™ NHL-1 phase 2 clinical trial evaluat...

Genmab Commences New Arbitration Under License Agreement With Janssen

Company Announcement

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement

Genmab to Participate in a Fireside Chat at the Goldman Sachs 43rd Annual Global Healthcare Conference

Media Release COPENHAGEN, Denmark ; June 8 , 20 2 2 Genmab A/S (Nasdaq: GMAB ) announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will partici...

Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical ...

COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced interim data from the innovaTV 205 trial, which included data evaluating t...

Other symbols: SGEN

Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical ...

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced interim data from the innovaTV 205 trial, which included data evaluating t...

Other symbols: SGEN

Major Shareholder Announcement

Company Announcement

Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, wi...

Genmab Announces Financial Results for the First Quarter of 2022

May 11 , 202 2 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2022

Should You Buy Genmab (GMAB) Ahead of Earnings?

Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Genmab (GMAB), AbbVie's Epcoritamab Successful in LBCL Study

Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response rate of ...

Other symbols: ABBV

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with ...

-          Based on topline results from the EPCORE™ NHL-1 clinical trial, AbbVie and Genmab will engage global regulatory authorities -          Data from the clinical trial to be presented at a future...

Other symbols: ABBV